An extensive portfolio of vaccines and constant rising demand has rendered the vaccine contract manufacturing market to be highly competitive with vast presence of key players across geographies. Along with safety and effectiveness of vaccines, flooding the market with one’s product clutches equal importance. In order to cater to the rising demand for vaccines and maintaining uniform quality, leading industrial players tend to outsource manufacturing of vaccines to third parties to expedite market entry.
Rising awareness of immunization across geographies contributes to the overall market growth of vaccine contract manufacturing. Additionally, government initiatives enforcing immunization globally has led to rising vaccine demand. The Global Vaccine Action Plan (GVAP) by the World Health Organization (WHO) is an initiative to prevent deaths via expanding the access of vaccines by 2020. As of May 2017, Health ministries across 194 countries endorsed a new initiative on strengthening immunization to meet the goals of GVAP. As per the WHO, around 19.5 million infants worldwide were still not provided with necessary vaccines. The ever-rising need for vaccines, and with established players primarily focusing on the development of other molecules, outsourcing is mostly the preferred choice. Additionally, in developing nations, the lack of suitable manufacturing set up and skilled labour compels them to engage with contract manufacturers in order to cater to market standards.
Vaccine contract manufacturers comply with the Good Manufacturing Practices and provide concerned quality assurance review documents. With newer advancements in vaccine production, the contract vendors constantly upgrade their production facilities providing up-to-date services. With initial development process taking place by industrial leaders, third parties are approached for scaling up processes.
Continuous partnerships and acquisitions further catalyse the overall market growth. In October 2017, DCPrime BV a firm developing dendritic cell vaccines for cancer therapy collaborated with apceth Biopharma GmbH contract manufacturer. The collaboration comprises clinical batch production and the development of expanded scale manufacturing process for cancer vaccines. However, a few large pharmaceutical firms prefer to maintain vaccine manufacturing in-house to avoid risks of management contingencies and deviation in safety and efficacy. This factor could have a negative impact on the global adoption of contract-based services during the forecast period.
The Global Vaccine Contract Manufacturing Market is segmented as follows:
Rising demand for expedited entry of vaccines into the market has rendered the vaccine contract manufacturing market to be highly competitive with a vast out reach across geographies. The key industrial players enjoying dominant position in this market are Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Cobra Biologics & Pharmaceutical Services, Cytovance Biologics; Catalent, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., IDT Biologika GmbH, Lonza Group, Ltd., Merck KGaA, Paragon Bioservices, Inc. and PRA Health Sciences.
This report offers: